Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial - LeMLAR trial

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2012
This article has no abstract
Epistemonikos ID: 7ac9429b63c71d188a629228c192cad9fab5e482
First added on: Apr 17, 2025